| Abstrakt: |
Keywords: Cambridge; United Kingdom; Europe; Adverse Drug Reactions; Biomarkers; Brain Diseases and Conditions; Cerebrosides; Diagnostics and Screening; Drugs and Therapies; Enzymes and Coenzymes; Fabry Disease; Genetics; Glucosylceramides; Health and Medicine; Lipid Metabolism Disorders; Lysosomal Storage Diseases and Conditions; Metabolic Diseases and Conditions; Neurology; Nutritional and Metabolic Diseases and Conditions; Sphingolipidoses; Synthase; X-Linked Genetic Diseases and Conditions EN Cambridge United Kingdom Europe Adverse Drug Reactions Biomarkers Brain Diseases and Conditions Cerebrosides Diagnostics and Screening Drugs and Therapies Enzymes and Coenzymes Fabry Disease Genetics Glucosylceramides Health and Medicine Lipid Metabolism Disorders Lysosomal Storage Diseases and Conditions Metabolic Diseases and Conditions Neurology Nutritional and Metabolic Diseases and Conditions Sphingolipidoses Synthase X-Linked Genetic Diseases and Conditions 402 402 1 04/10/23 20230410 NES 230410 2023 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Nutritional and Metabolic Diseases and Conditions - Fabry Disease. Cambridge, United Kingdom, Europe, Adverse Drug Reactions, Biomarkers, Brain Diseases and Conditions, Cerebrosides, Diagnostics and Screening, Drugs and Therapies, Enzymes and Coenzymes, Fabry Disease, Genetics, Glucosylceramides, Health and Medicine, Lipid Metabolism Disorders, Lysosomal Storage Diseases and Conditions, Metabolic Diseases and Conditions, Neurology, Nutritional and Metabolic Diseases and Conditions, Sphingolipidoses, Synthase, X-Linked Genetic Diseases and Conditions. [Extracted from the article] |
